An evolutionary differential game for regulating the role of monoclonal antibodies in treating signalling pathways in oesophageal cancer
Open Access
- 31 July 2024
- journal article
- research article
- Published by The Royal Society in Royal Society Open Science
- Vol. 11 (7) , 240347
Abstract
This work presents a new framework for a competitive evolutionary game between monoclonal antibodies and signalling pathways in oesophageal cancer. The framework is based on a novel dynamical model that takes into account the dynamic progression of signalling pathways, resistance mechanisms and monoclonal antibody therapies. This game involves a scenario in which signalling pathways and monoclonal antibodies are the players competing against each other, where monoclonal antibodies use Brentuximab and Pembrolizumab dosages as strategies to counter the evolutionary resistance strategy implemented by the signalling pathways. Their interactions are described by the dynamical model, which serves as the game’s playground. The analysis and computation of two game-theoretic strategies, Stackelberg and Nash equilibria, are conducted within this framework to ascertain the most favourable outcome for the patient. By comparing Stackelberg equilibria with Nash equilibria, numerical experiments show that the Stackelberg equilibria are superior for treating signalling pathways and are critical for the success of monoclonal antibodies in improving oesophageal cancer patient outcomes.Keywords
Funding Information
- Division of Mathematical Sciences
This publication has 39 references indexed in Scilit:
- Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I StudyJournal of Clinical Oncology, 2014
- Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cellsFEBS Letters, 2013
- Exploiting ecological principles to better understand cancer progression and treatmentInterface Focus, 2013
- Evolutionary foundations for cancer biologyEvolutionary Applications, 2013
- Applying ecological and evolutionary theory to cancer: a long and winding roadEvolutionary Applications, 2012
- Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational OncologyBiotechnology Advances, 2012
- Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypesClinical and Experimental Immunology, 2011
- Evolutionary Dynamics in Cancer TherapyMolecular Pharmaceutics, 2011
- Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?2011
- Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung CancerClinical Cancer Research, 2006